Kazia Therapeutics Appoints James Levine as Chief Financial Officer
KZIA has more than doubled off its 52-week low of $3.544.
Summary
Kazia Therapeutics appointed James Levine, an experienced biotech finance executive, as its new Chief Financial Officer, bringing significant capital markets expertise and a substantial equity incentive package.
Key Events · Executive and Board Changes · KZIA
-
New Chief Financial Officer Appointed
James Levine, with over two decades of experience in investment banking and biotech financial leadership, has been appointed CFO, effective June 1, 2026.
-
Significant Compensation Package
Mr. Levine will receive an annual base salary of US$475,000, a target bonus of 40% of his base salary, and options over 200,000 American Depositary Shares (ADSs).
-
Strategic Expertise
His background includes leading financial strategy, strategic transactions, and major pharmaceutical collaborations at companies like Cardiff Oncology and Cidara Therapeutics, and 12 years at Goldman Sachs.
Analysis · KZIA · Life Sciences
The appointment of James Levine as Chief Financial Officer brings over two decades of experience in investment banking and biotech financial leadership to Kazia Therapeutics. His expertise is crucial for a clinical-stage oncology company navigating capital markets and strategic transactions. The compensation package, including a substantial equity grant of 200,000 ADSs (potentially valued at over $2.5 million), aligns his interests with long-term shareholder value.
At the time of this filing, KZIA was trading at $12.87 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $142.4M. The 52-week trading range was $3.54 to $17.40. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.